NASDAQ : CNTB
Connect Biopharma Holdings Limited — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8022 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 50.52M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 50.52M |
| Enterprise Value | 19.63M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 62.97M |
| Shares Outstanding | 62.97M |
| Shares Change (YoY) | +4.44% |
| Shares Change (QoQ) | +11.21% |
| Owned by Insiders (%) | 15.19% |
| Owned by Institutions (%) | 19.33% |
| Float | 17.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.11 |
| Forward PS | 6.52 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 1.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.37 |
| Quick Ratio | 2.11 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -140.51% |
| Return on Assets (ROA) | -69.75% |
| Return on Invested Capital (ROIC) | -88.31% |
| Return on Capital Employed (ROCE) | -259.15% |
| Weighted Average Cost of Capital (WACC) | 3.21% |
| Revenue Per Employee | $46,141 |
| Profits Per Employee | -$1.08M |
| Employee Count | 64 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 196,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.18 |
| 52-Week Price Change | -49.32% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 32.96 |
| Average Volume (20 Days) | 1,156,649 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.86M |
| Short Previous Month | 3.50M |
| Short % of Shares Out | 8.69% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.95M |
| Gross Profit | 2.95M |
| Operating Income | -70.41M |
| Pretax Income | -68.80M |
| Net Income | -68.99M |
| EBITDA | -69.73M |
| EBIT | -70.41M |
| Loss Per Share | -$1.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 31.49M |
| Total Debt | 596,000 |
| Net Cash | 30.89M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 26.86M |
| Book Value Per Share | 0.43 |
| Working Capital | 22.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -60.58M |
| Capital Expenditures | -50,000 |
| Depreciation & Amortization | 685,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -60.63M |
| FCF Per Share | -$0.96 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -2,384.49% |
| Pretax Margin | -2,329.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.44% |
| Shareholder Yield | -4.44% |
| Earnings Yield | -148.76% |
| FCF Yield | -120.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.00 |
| Price Target Difference | 647.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 487.12% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -13.9 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |